Novo Nordisk/NVO

$132.68

-1.04%
-
1D1W1MYTD1YMAX

About Novo Nordisk

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Ticker

NVO

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Lars Fruergaard Joergensen

Employees

66,015

Headquarters

Bagsvaerd, Denmark

Novo Nordisk Metrics

BasicAdvanced
$454B
Market cap
47.00
P/E ratio
$2.90
EPS
0.42
Beta
$1.02
Dividend rate
0.38%
Dividend yield
$454B
0.42021
$138.28
$75.56
4.6M
$1.02
0.703
0.5
16.949
27.224
47.03%
247.496
32.53%
99.87%
71.03%
46.998
12.766
42.18
79.394
374.883
1.31%
0.75%
0.38%
29.72%
48.15%
22.31%
27.4%
20.59%

What the Analysts think about Novo Nordisk

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
10.01% upside
High $162.71
Low $129.77
$132.68
Current price
$145.96
Average price target

Novo Nordisk Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
38.87% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
kr 65B
-0.78%
Net income
kr 25B
15.68%
Profit margin
38.87%
16.59%

Novo Nordisk Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.57%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
kr 4.32
kr 5.00
kr 4.91
kr 5.68
-
Expected
kr 4.41
kr 5.00
kr 4.48
kr 5.14
kr 5.57
Surprise
-2.09%
0.09%
9.55%
10.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Novo Nordisk stock?

Novo Nordisk (NVO) has a market cap of $454B as of May 29, 2024.

What is the P/E ratio for Novo Nordisk stock?

The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 47 as of May 29, 2024.

Does Novo Nordisk stock pay dividends?

Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of May 29, 2024, the dividend rate is $1.01694 and the yield is 0.38%. Novo Nordisk has a payout ratio of 47.03% on a trailing twelve-month basis.

When is the next Novo Nordisk dividend payment date?

The next Novo Nordisk (NVO) dividend payment date is unconfirmed.

What is the beta indicator for Novo Nordisk?

Novo Nordisk (NVO) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Novo Nordisk stock price target?

The target price for Novo Nordisk (NVO) stock is $145.96, which is 10.01% above the current price of $132.68. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Novo Nordisk stock

Buy or sell Novo Nordisk stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing